Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Systemic Pharmacokinetics of Icenticaftor in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Control Participants

ClinicalTrials.gov Identifier: NCT04587622

Novartis Reference Number: CQBW251A2104

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

The primary purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with varying degrees of hepatic impairment.

Condition 
Hepatic Failure
Phase 
Phase 1
Overall status 
Not yet recruiting
Enrollment count 
48 participants
Start date 
Oct 19, 2020
Completion date 
Nov 19, 2021
Gender 
All
Age(s)
18 Years - 75 Years (Adult, Older Adult)

Interventions

Drug
Icenticaftor
Single oral dose of 300 mg of icenticaftor (QBW251)

Eligibility Criteria

All Participants:

Inclusion Criteria:

Male and non-child bearing potential female participants, 18 to 75 years of age (inclusive) at Screening.
Participants must weigh at least 50.0 kg and must have a body mass index (BMI) within the range of 18.0 to 38.0 kg/m2, inclusive, at Screening.
Must be a non-smoker or agree to smoke no more than 5 cigarettes (or equivalent) per day from Screening until the End of Study. Participants must maintain the same smoking status throughout the study (i.e. smoker or non smoker).

Exclusion Criteria:

Use of other investigational drugs within 5 half-lives prior to dosing of study treatment, or within 30 days, whichever is longer; or longer if required by local regulations.
Are taking medications prohibited to be taken with the study treatment
Known history of, or current clinically significant arrhythmias. Have clinically significant ECG abnormality or history of long-QT syndrome or whose QT interval corrected by Fridericia's formula (QTcF) is prolonged (> 480 msec) at Screening. Participants having myocardial infarction ≥ 5 years ago are eligible to participate.
Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection.

Healthy Participants:

Each participant must match in age (± 10 years), gender, weight (± 15%), and smoking status to participants in Group 2, 3, or 4.
Seated vital signs must be within the following ranges at Screening and Baseline:
Body temperature, 35.0 to 37.5°C, inclusive.
Systolic blood pressure, 89 to 149 mmHg, inclusive.
Diastolic blood pressure, 50 to 89 mmHg, inclusive.
Pulse rate, 40 to 90 bpm, inclusive.
Participants must be in good health as determined by medical history, physical examination, ECG, and clinical laboratory tests at Screening.

Exclusion Criteria:

Liver disease or liver injury as indicated by abnormal liver function tests.
Chronic infection with HBV or HCV.
History or presence of impaired renal function.

Hepatic Impairment Participants:

Inclusion Criteria:

Seated vital signs must be within the following ranges at Screening and Baseline:
Body temperature, 35.0 to 37.5°C, inclusive.
Systolic blood pressure, 89 to 159 mmHg, inclusive.
Diastolic blood pressure, 50 to 99 mmHg, inclusive.
Pulse rate, 50 to 99 bpm, inclusive.
Hepatic impairment as defined by the Child-Pugh classification for severity of liver disease

Exclusion Criteria:

Have severe complications of liver disease within the preceding 3 months of Screening.
Emergency room visit or hospitalization due to liver disease within the preceding 3 months of Screening.
Have received liver transplant at any time in the past.
Have encephalopathy Grade 3 or worse within 28 days prior to dosing of study treatment.
Have acute hepatitis B (HBV) or hepatitis C (HCV) infection.
Clinically significant abnormal findings in physical examination or clinical laboratory evaluations not consistent with known liver disease.

Other protocol-defined inclusion/exclusion criteria may apply

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
1-888-669-6682
Name: 
Novartis Pharmaceuticals
Phone: 
Email: 

Have a question?

Call 1-999-669-6682 or email [email protected]